Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody
that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and SBRT (focused
radiation) is effective (anti-tumor activity) and safe in patients with locally advanced
pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins